Going beyond the first fill: Prime Therapeutics, NCODA collaboration enables improved patient outcomes through new oncology pharmacy accreditation

Accredited medically integrated pharmacies may become eligible to participate in Prime’s IntegratedRx™ - Oncology network

October 19, 2021

EAGAN, Minn. and CAZENOVIA, NY –  Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM) serving more than 33 million members, will prefer for its IntegratedRx™  – Oncology program the new specialized accreditation from NCODA, the leading nonprofit association for the patient-centered medically integrated oncology community. This first-in-market accreditation – which aligns with Prime’s essential accreditation criteria – is a component of required credentialling for IntegratedRx – Oncology.

IntegratedRx – Oncology streamlines the treatment pathway for members and providers through its best-in-care integrated dispensing model. With IntegratedRx, members can receive their medicine through the oncology clinic’s integrated pharmacy, where the provider and pharmacist are part of the same team, allowing for direct lines of communication. This end-to-end coordination across the treatment pathway helps improve adherence, shortens time to dispense, and creates a better patient outcome and provider experience from the first fill to the last fill.

NCODA recently announced its new Center of Excellence (CoE) Medically Integrated Pharmacy (MIP) Accreditation Program. The program, based on compliance with the ASCO/NCODA Patient-Centered Standards for Medically Integrated Dispensing, focuses on enhanced patient care and quality of services.  NCODA is committed to empowering medically integrated pharmacies to deliver the highest level of performance that brings sustainability and value for all stakeholders. This program achieves the quadruple aim goals of improved clinician experience, better outcomes, lower costs, and improved patient experience. The key areas of focus include medication adherence, patient education and safety, cost avoidance and waste reduction, continuous quality improvement, financial assistance and patient satisfaction.

“Current accreditation standards don’t take into account the advantages of integrated pharmacy dispensing, said Joseph Leach, M.D., chief medical officer for Prime and a practicing oncologist. “Prime prefers NCODA’s MIP accreditation as it meets our quality requirements while reducing the burden associated with some broad accreditations, especially for oncology-specific pharmacies. It’s a perfect fit for the IntegratedRx dispensing model.”

Elizabeth Bell, director of medically integrated pharmacy accreditation for NCODA, said, “NCODA sees the IntegratedRx – Oncology program as a groundbreaking initiative. Allowing credentialed and accredited medically integrated oncology pharmacies to go beyond the first fill provides better patient outcomes and lower cost to the patient, practice, health plan and employer. Our patient-centered accreditation program was designed specifically for medically integrated oncology pharmacies and aligns perfectly with the IntegratedRx – Oncology program.”

Leach and Bell will introduce the accreditation to the medically integrated oncology community Oct. 22 at the NCODA Fall Summit in Scottsdale, Ariz.

Related news

Press releases

November 3, 2021

Prime Therapeutics backs first interchangeable insulin biosimilar Semglee®

EAGAN, Minn. – Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM)…

Press releases

October 18, 2021

Cancer patients, caregivers benefit with integrated clinic-to-pharmacy care through Prime Therapeutics’ IntegratedRx™ – Oncology

EAGAN, Minn. – Prime Therapeutics, a leading pharmacy benefit manager (PBM) serving more…

Press releases

October 14, 2021

In first of its kind study, Prime Therapeutics explores paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor treatment rates

EAGAN, Minn. – Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its…